What's Happening?
Thermo Fisher Scientific Inc. has announced the global launch of the Gibco CTS Compleo Fill and Finish System, an automated and functionally closed solution designed to streamline the formulation and filling processes in cell therapy manufacturing. This
system addresses the variability in cell count, concentration, and viability that often arises from patient-derived cells used in therapies. By reducing manual intervention, the system aims to improve operational efficiency while maintaining strict sterility, dose accuracy, and product consistency. The CTS Compleo system offers a compact, automated solution that reduces the risk of contamination and supports consistent batch-to-batch performance. Early adopters, such as Arsenal Biosciences, Inc., have reported benefits in reducing variability and streamlining manufacturing processes.
Why It's Important?
The introduction of the CTS Compleo system is significant for the cell therapy industry, which is increasingly moving towards commercialization. The system's ability to automate and close the formulation and filling processes can lead to more reliable and consistent manufacturing outcomes. This advancement is crucial as it helps manufacturers meet the growing demand for cell therapies while ensuring product quality and safety. By improving efficiency and reducing the risk of contamination, the system supports the delivery of life-changing therapies to patients more rapidly. This development could potentially lower production costs and increase accessibility to advanced therapies, benefiting both manufacturers and patients.
What's Next?
Thermo Fisher Scientific plans to showcase the CTS Compleo system and its Gibco Cell Therapy Systems portfolio at upcoming industry events, including the International Society for Cell & Gene Therapy and the American Society of Gene & Cell Therapy annual meetings. The company also offers comprehensive services to support the implementation of the system, including installation, application, and process development support. As more manufacturers adopt this technology, it is expected to become a standard in the industry, further driving innovation and efficiency in cell therapy manufacturing.
